AVEN Polyclonal Antibody, Cy5.5 Conjugated
Applications
Reactivity
Predicted Reactivity
| Overview | |
| Catalog # | bs-2438R-Cy5.5 |
| Product Name | AVEN Polyclonal Antibody, Cy5.5 Conjugated |
| Applications |
WB
IF(IHC-P)
IF(IHC-F)
IF(ICC)
|
| Reactivity | Mouse, Rat |
| Predicted Reactivity | Human, Pig, Horse, Chicken, Rabbit |
| Specifications | |
| Conjugation | Cy5.5 |
| Host | Rabbit |
| Source | KLH conjugated synthetic peptide derived from human AVEN |
| Clonality | Polyclonal |
| Isotype | IgG |
| Concentration | 1ug/ul |
| Purification | Purified by Protein A. |
| Storage Buffer | Aqueous buffered solution containing 0.01M TBS (pH 7.4) with 1% BSA, 0.02% Proclin300 and 50% Glycerol. |
| Storage Condition | Store at -20C. Aliquot into multiple vials to avoid repeated freeze-thaw cycles. |
| Target | |
| Gene ID | 57099 |
| Subcellular location | Cell membrane |
| Synonyms | 1700013A01Rik; 1700056A21Rik; mAven L; mAven S; MGC124011; Apoptosis caspase activation inhibitor; Cell death regulator Aven; OTTMUSP00000016129; PDCD12; Programmed cell death 12; RP23-52C15.2; AVEN_HUMAN |
| Background | Apoptosis plays a major role in normal organism development, tissue homeostasis, and removal of damaged cells. Disruption of this process has been implicated in a variety of diseases such as cancer. AVEN is a recently discovered protein that blocks apoptosis induced by Apaf-1 and caspase-9. It is thought that AVEN functions by binding to Bcl-xL, an antiapoptotic member of the Bcl-2 family, and to Apaf-1, possibly interfering with the ability of Apaf-1 to self-associate, suggesting that AVEN impedes Apaf-1-mediated caspase activation. Higher levels of AVEN mRNA are seen in patients with acute leukemia than in control patients, suggesting that AVEN may be useful as a prognostic indicator in leukemia patients. |
| Application Dilution | |
| WB | 1:300-5000 |
| IF(IHC-P) | 1:50-200 |
| IF(IHC-F) | 1:50-200 |
| IF(ICC) | 1:50-200 |